2 cheap growth stocks I’d buy for the long term

These two shares could offer a mix of growth and value in current market conditions.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Despite the recent pullback across the stock market, investor sentiment is generally upbeat. Certainly, the FTSE 100 has dropped by over 10% since its all-time high of a few months ago, but we are technically still in a bull market which could have further to run.

Therefore, buying stocks after the recent fall could be a wise move. They may offer greater volatility than expected, but their margins of safety now appear to be relatively wide. With that in mind, here are two stocks that could be worth a closer look today.

Improving outlook

Reporting on Monday was regenerative medical devices company Tissue Regenix (LSE: TRX). The performance of the business in 2017 was relatively encouraging, with its revenue increasing more than three-fold to £5.2m. It was able to launch additional product lines, addressing surgical reconstructive procedures and dental applications.

The company’s £40m equity fundraise was successful and it was able to complete the acquisition of CellRight Technologies in August 2017. This has the potential to boost its financial performance over the medium term, with the stock expected to move into profitability in the next financial year. This follows a long period of lossmaking and could help to improve investor sentiment.

Although Tissue Regenix trades on a forward price-to-earnings (P/E) ratio of around 60, the company could deliver earnings growth in future years. It is entering a new phase of commercialisation which could produce a step-change in financial performance. As such, the company could prove to be a strong performer within what remains a relatively enticing wider healthcare industry.

Growth potential

Also offering upbeat investment potential is Hikma Pharmaceuticals (LSE: HIK). The company is in the midst of a challenging period which has seen its bottom line decline in each of the last three years. This has contributed to a fall in its share price of 45% in the last year. And with it due to report a further decline in its bottom line of 11% in the current year, its short-term performance could be somewhat disappointing.

However, over the medium term the company could experience an improvement in its share price performance. It is forecast to report a rise in earnings of 14% in the next financial year and this may lead to a change in investor sentiment. Since Hikma has a price-to-earnings growth (PEG) ratio of just 1.1, there seems to be significant upside potential on offer. As such, it could prove to be a strong turnaround play.

The healthcare industry could become increasingly popular in future. If the wider stock market remains volatile then investors may seek stocks that could offer lower positive correlation with the index. As such, buying Hikma right now could be a profitable move over the long run, while providing some protection against share price falls in the short run.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of Hikma Pharmaceuticals. The Motley Fool UK has recommended Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young black man looking at phone while on the London Overground
Investing Articles

Investing £3.33 into an ISA every day from 22 could result in a £60,000 passive income

Millions of Britons use the Stocks and Shares ISA as a way to build wealth and generate an income. However,…

Read more »

Investing Articles

2 resurgent cheap shares that could skyrocket in 2025

Cheap shares can take our portfolios to the next level. Here, Dr James Fox highlights two stocks that appear to…

Read more »

Investing Articles

How much does an investor need in a Stocks and Shares ISA to earn £1,000 a month in passive income?

A Stocks and Shares ISA's a valuable asset for investors. Not having to pay dividend tax can be a big…

Read more »

Investing Articles

9% dividend yield! Could buying this FTSE 250 stock earn me massive passive income?

Assura looks like an outstanding stock for dividend investors to consider. But is the 9% dividend yield the passive income…

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

Why I think this month could be critical for the Lloyds share price!

Our writer explains why he thinks the bank's 2024 results will have a significant impact on the short-term direction of…

Read more »

British Pennies on a Pound Note
Investing Articles

This former penny share has soared 168%. Is the best yet to come?

When Christopher Ruane saw a penny share as a potential bargain last year, he was spot on. So having not…

Read more »

Mature couple at the beach
Investing Articles

£20k in an ISA? Here’s how it could generate £1 of passive income every hour — forever

With a long-term approach, Christopher Ruane explains how an investor could aim to earn a pound per hour in passive…

Read more »

One English pound placed on a graph to represent an economic down turn
Investing Articles

FTSE shares: overpriced or still a bargain?

Christopher Ruane reckons a storming FTSE 100 performance of late doesn't tell us much about whether there are still possible…

Read more »